Please login to the form below
Pharmaceutical Market Europe (PME)
PME is a monthly print and digital title written by experienced journalists and high-profile pharma and healthcare experts. The magazine provides insights and offers solutions to the issues that keep industry leaders awake at night.
From the latest developments in cancer treatments and the strategies behind them to new marketing and commercialisation models and the regulations that underpin the fabric of the sector – PME's got it covered.
PME is a trusted source for decision makers and influencers in pharma and healthcare who, through the practical and accessible content, have the knowledge to tackle whatever comes their way.
Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
ARV-471 is currently in a phase 2 trial for the treatment of patients ER-positive, HER2-negative locally advanced or metastatic breast cancer
Roche engaged in talks with FDA for Alzheimer’s drug candidate
CEO Severin Schwan told reporters Roche will complete a phase 3 trial of gantenerumab in the second half of 2022
One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
New real-world data from Canada shows vaccine efficacy was lower against milder symptomatic disease with one dose
J&J, distributors reach $26bn settlement to address the opioid crisis in the US
The proposed agreement would resolve claims of both states and local governments in the US
Articles
-
The future of work has been just around the corner for some time...by Rachael Yolland
-
Paving the way for the HCP omnichannel experience: a guide for medical affairsBy Stephen Jones
-
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannelChris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence
-
Pharma’s authentic proof of purpose influences decisions among HCPs and payersBy Ludivine Delattre and Stacy Vaughn
-
Mastering oneself What does it take to be a biomedical strategy expert?
Pharmaceutical Market Europe - July/August 2021
Omnichannel communications, The importance of the patient voice in clinical trials, Hybrid working – making the new normal work for everyone
Pharmaceutical Market Europe (PME) magazine is also available on the iPhone/iPad as a free app
Editor - Iona Everson
Have your say...
Subscribe
Mark Caulfield departs from Genomics England to take on CEO role at Barts Life Sciences
Caulfield served as chief scientist at Genomics England, working on the 100,000 Genomes Project
'Nothing about us without us'
Why patient engagement is essential throughout the entire product life cycle
Ashfield launches ‘end-to-end’ cell and gene therapy commercialisation network
The network, called EmerGENE, combines experts from Ashfield Health, Ashfield Engage and Ashfield Advisory
COVID-19 Updates and Daily News
Featured jobs
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital account director
-
Competitive
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Digital project manager
-
Competitive
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
-
Digital strategist
-
Competitive
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- GSK reveals plans for £400m R&D facility expansion in England
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The future of work has been just around the corner for some time...
- Investigating the Complexities of the Canadian & Global Health Systems
- Impetus Digital Overview
- Amgen signs $180m nanotechnology cancer deal
- British officials reportedly monitoring Philip Morris’ proposed acquisition of Vectura
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- AZ’s comeback drug cediranib stumbles in phase 3 trial
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- MHRA outlines two-year delivery plan with ‘patient first’ focus
PMHub
Say Communications
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...
Latest intelligence
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
- Virtual Speaker Program: A Customer Story
- Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....
